| Age, (years) . | Gender . | KPS . | Disease status . | Focality . | Tumor localization . | Prior treatment . | Disease status prior to pemetrexed . | Time between last treatment and start of pemetrexed, (months) . | Dose . | Cycle number . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76 | F | 60 | PCNSL | Multi | Frontal lobe, thalamus/basal ganglia | HD‐MTX | Relapse | 1 | 600 | 2 | PR |
| 77 | M | 60 | PCNSL | Uni | Occipital lobe | HD‐MTX | Relapse | 1 | 600 | 5 | PR |
| 66 | M | 90 | PCNSL | Uni | Midbrain/pons | (a) HD‐MTX, (b) MTX‐thiotepa | Relapse | 38 | 600 | 10 | PR |
| 68 | F | 80 | PCNSL | Uni | Temporal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 4 | PD |
| 64 | M | 80 | PCNSL | Uni | Thalamus/basal ganglia | HD‐MTX | Intolerant to MTX | 1 | 600 | 7 | PR |
| 53 | F | 90 | PCNSL | Uni | Parietal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 2 | PD |
| 71 | M | 80 | SCNSL | Uni | Corpus callosum | (a) HD‐MTX, (b) R‐CHOP, (c) radiation | Relapse | 2 | 900 | 5 | SD |
| 67 | M | 70 | SCNSL | Uni | Fronto‐parieto‐temporal | (a) R‐CHOP, (b) HD‐MTX | Relapse | 1 | 900 | 4 | PD |
| 54 | F | 100 | PCNSL | Uni | Frontal lobe | MTX‐TMZ‐R, then cytarabine/etoposide | Relapse | 19 | 900 | 10 | CR |
| 49 | M | 90 | PCNSL | Multi | Frontal lobe | (a) R‐EPOCH avastin + MTXi, (b) MTX‐TMZ‐R, R‐Ara‐C, and radiation | Relapse | 1 | 1,200 | 1 | — |
| 72 | F | 100 | PCNSL | Multi | Frontal/temporal lobe | MTX‐TMZ | Relapse | 4 | 1,200 | 10 | SD |
| 66 | F | 100 | PCNSL | Uni | Temporal lobe | (a) HD‐MTX, (b) HD‐MTX‐R and radiation, (c) HD‐MTX | Relapse | 1 | 1,200 | 12 | CR |
| 51 | M | 90 | PCNSL | Uni | Corpus callosum | MTX‐TMZ‐R then ASCT | Relapse | 44 | 1,200 | 6 | PR |
| 61 | M | 80 | SCNSL | Uni | Parietal lobe | (a) R‐CVP, (b) R‐CHOP, (c) HD‐MTX | Refractory | 1 | 1,200 | 1 | — |
| 47 | M | 60 | PCNSL | Multi | Cerebellum | HD‐MTX‐TMZ‐R then ASCT | Relapse | 30 | 1,200 | 10 | CR |
| 68 | F | * | PCNSL | Multi | Parieto‐occipital lobe | (a) HD‐MTX, (b) ioMTX, (c) ioMTX | Relapse | 24 | 900 | 1 | — |
| 73 | F | 90 | PCNSL | Multi | Parietal lobe, periventricular, mid brain | MTX‐TMZ‐R, Ara‐C | Relapse | 11 | 1,200 | 3 | PD |
| Age, (years) . | Gender . | KPS . | Disease status . | Focality . | Tumor localization . | Prior treatment . | Disease status prior to pemetrexed . | Time between last treatment and start of pemetrexed, (months) . | Dose . | Cycle number . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76 | F | 60 | PCNSL | Multi | Frontal lobe, thalamus/basal ganglia | HD‐MTX | Relapse | 1 | 600 | 2 | PR |
| 77 | M | 60 | PCNSL | Uni | Occipital lobe | HD‐MTX | Relapse | 1 | 600 | 5 | PR |
| 66 | M | 90 | PCNSL | Uni | Midbrain/pons | (a) HD‐MTX, (b) MTX‐thiotepa | Relapse | 38 | 600 | 10 | PR |
| 68 | F | 80 | PCNSL | Uni | Temporal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 4 | PD |
| 64 | M | 80 | PCNSL | Uni | Thalamus/basal ganglia | HD‐MTX | Intolerant to MTX | 1 | 600 | 7 | PR |
| 53 | F | 90 | PCNSL | Uni | Parietal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 2 | PD |
| 71 | M | 80 | SCNSL | Uni | Corpus callosum | (a) HD‐MTX, (b) R‐CHOP, (c) radiation | Relapse | 2 | 900 | 5 | SD |
| 67 | M | 70 | SCNSL | Uni | Fronto‐parieto‐temporal | (a) R‐CHOP, (b) HD‐MTX | Relapse | 1 | 900 | 4 | PD |
| 54 | F | 100 | PCNSL | Uni | Frontal lobe | MTX‐TMZ‐R, then cytarabine/etoposide | Relapse | 19 | 900 | 10 | CR |
| 49 | M | 90 | PCNSL | Multi | Frontal lobe | (a) R‐EPOCH avastin + MTXi, (b) MTX‐TMZ‐R, R‐Ara‐C, and radiation | Relapse | 1 | 1,200 | 1 | — |
| 72 | F | 100 | PCNSL | Multi | Frontal/temporal lobe | MTX‐TMZ | Relapse | 4 | 1,200 | 10 | SD |
| 66 | F | 100 | PCNSL | Uni | Temporal lobe | (a) HD‐MTX, (b) HD‐MTX‐R and radiation, (c) HD‐MTX | Relapse | 1 | 1,200 | 12 | CR |
| 51 | M | 90 | PCNSL | Uni | Corpus callosum | MTX‐TMZ‐R then ASCT | Relapse | 44 | 1,200 | 6 | PR |
| 61 | M | 80 | SCNSL | Uni | Parietal lobe | (a) R‐CVP, (b) R‐CHOP, (c) HD‐MTX | Refractory | 1 | 1,200 | 1 | — |
| 47 | M | 60 | PCNSL | Multi | Cerebellum | HD‐MTX‐TMZ‐R then ASCT | Relapse | 30 | 1,200 | 10 | CR |
| 68 | F | * | PCNSL | Multi | Parieto‐occipital lobe | (a) HD‐MTX, (b) ioMTX, (c) ioMTX | Relapse | 24 | 900 | 1 | — |
| 73 | F | 90 | PCNSL | Multi | Parietal lobe, periventricular, mid brain | MTX‐TMZ‐R, Ara‐C | Relapse | 11 | 1,200 | 3 | PD |
Abbreviations: *, not evaluable; CR, complete response; F, female; HD‐MTX, high‐dose methotrexate; HD‐MTX‐R, high‐dose methotrexate rituximab; ioMTX, intraocular methotrexate; KPS, Karnofsky performance status; M, male; MTXi, methotrexate intrathecal; MTX‐TMZ‐R, methotrexate temozolomide rituximab; OS, overall survival; PCSNL, primary central system nervous lymphoma; PD, progressive disease; PFS, progression‐free survival; PR, partial response; R‐Ara‐C, rituximab cytarabine; R‐CHOP, rituximab cyclophosphamide hydroxydaunomycin oncovin prednisone; R‐CVP, rituximab cyclophosphamide vincristine prednisone; R‐EPOCH, rituximab etoposide prednisone oncovin cyclophosphamide hydroxydaunomycin; SCNL, secondary central system nervous lymphoma; SD, stable disease.
| Age, (years) . | Gender . | KPS . | Disease status . | Focality . | Tumor localization . | Prior treatment . | Disease status prior to pemetrexed . | Time between last treatment and start of pemetrexed, (months) . | Dose . | Cycle number . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76 | F | 60 | PCNSL | Multi | Frontal lobe, thalamus/basal ganglia | HD‐MTX | Relapse | 1 | 600 | 2 | PR |
| 77 | M | 60 | PCNSL | Uni | Occipital lobe | HD‐MTX | Relapse | 1 | 600 | 5 | PR |
| 66 | M | 90 | PCNSL | Uni | Midbrain/pons | (a) HD‐MTX, (b) MTX‐thiotepa | Relapse | 38 | 600 | 10 | PR |
| 68 | F | 80 | PCNSL | Uni | Temporal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 4 | PD |
| 64 | M | 80 | PCNSL | Uni | Thalamus/basal ganglia | HD‐MTX | Intolerant to MTX | 1 | 600 | 7 | PR |
| 53 | F | 90 | PCNSL | Uni | Parietal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 2 | PD |
| 71 | M | 80 | SCNSL | Uni | Corpus callosum | (a) HD‐MTX, (b) R‐CHOP, (c) radiation | Relapse | 2 | 900 | 5 | SD |
| 67 | M | 70 | SCNSL | Uni | Fronto‐parieto‐temporal | (a) R‐CHOP, (b) HD‐MTX | Relapse | 1 | 900 | 4 | PD |
| 54 | F | 100 | PCNSL | Uni | Frontal lobe | MTX‐TMZ‐R, then cytarabine/etoposide | Relapse | 19 | 900 | 10 | CR |
| 49 | M | 90 | PCNSL | Multi | Frontal lobe | (a) R‐EPOCH avastin + MTXi, (b) MTX‐TMZ‐R, R‐Ara‐C, and radiation | Relapse | 1 | 1,200 | 1 | — |
| 72 | F | 100 | PCNSL | Multi | Frontal/temporal lobe | MTX‐TMZ | Relapse | 4 | 1,200 | 10 | SD |
| 66 | F | 100 | PCNSL | Uni | Temporal lobe | (a) HD‐MTX, (b) HD‐MTX‐R and radiation, (c) HD‐MTX | Relapse | 1 | 1,200 | 12 | CR |
| 51 | M | 90 | PCNSL | Uni | Corpus callosum | MTX‐TMZ‐R then ASCT | Relapse | 44 | 1,200 | 6 | PR |
| 61 | M | 80 | SCNSL | Uni | Parietal lobe | (a) R‐CVP, (b) R‐CHOP, (c) HD‐MTX | Refractory | 1 | 1,200 | 1 | — |
| 47 | M | 60 | PCNSL | Multi | Cerebellum | HD‐MTX‐TMZ‐R then ASCT | Relapse | 30 | 1,200 | 10 | CR |
| 68 | F | * | PCNSL | Multi | Parieto‐occipital lobe | (a) HD‐MTX, (b) ioMTX, (c) ioMTX | Relapse | 24 | 900 | 1 | — |
| 73 | F | 90 | PCNSL | Multi | Parietal lobe, periventricular, mid brain | MTX‐TMZ‐R, Ara‐C | Relapse | 11 | 1,200 | 3 | PD |
| Age, (years) . | Gender . | KPS . | Disease status . | Focality . | Tumor localization . | Prior treatment . | Disease status prior to pemetrexed . | Time between last treatment and start of pemetrexed, (months) . | Dose . | Cycle number . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 76 | F | 60 | PCNSL | Multi | Frontal lobe, thalamus/basal ganglia | HD‐MTX | Relapse | 1 | 600 | 2 | PR |
| 77 | M | 60 | PCNSL | Uni | Occipital lobe | HD‐MTX | Relapse | 1 | 600 | 5 | PR |
| 66 | M | 90 | PCNSL | Uni | Midbrain/pons | (a) HD‐MTX, (b) MTX‐thiotepa | Relapse | 38 | 600 | 10 | PR |
| 68 | F | 80 | PCNSL | Uni | Temporal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 4 | PD |
| 64 | M | 80 | PCNSL | Uni | Thalamus/basal ganglia | HD‐MTX | Intolerant to MTX | 1 | 600 | 7 | PR |
| 53 | F | 90 | PCNSL | Uni | Parietal lobe | MTX‐TMZ‐R then HD‐MTX | Relapse | 1 | 600 | 2 | PD |
| 71 | M | 80 | SCNSL | Uni | Corpus callosum | (a) HD‐MTX, (b) R‐CHOP, (c) radiation | Relapse | 2 | 900 | 5 | SD |
| 67 | M | 70 | SCNSL | Uni | Fronto‐parieto‐temporal | (a) R‐CHOP, (b) HD‐MTX | Relapse | 1 | 900 | 4 | PD |
| 54 | F | 100 | PCNSL | Uni | Frontal lobe | MTX‐TMZ‐R, then cytarabine/etoposide | Relapse | 19 | 900 | 10 | CR |
| 49 | M | 90 | PCNSL | Multi | Frontal lobe | (a) R‐EPOCH avastin + MTXi, (b) MTX‐TMZ‐R, R‐Ara‐C, and radiation | Relapse | 1 | 1,200 | 1 | — |
| 72 | F | 100 | PCNSL | Multi | Frontal/temporal lobe | MTX‐TMZ | Relapse | 4 | 1,200 | 10 | SD |
| 66 | F | 100 | PCNSL | Uni | Temporal lobe | (a) HD‐MTX, (b) HD‐MTX‐R and radiation, (c) HD‐MTX | Relapse | 1 | 1,200 | 12 | CR |
| 51 | M | 90 | PCNSL | Uni | Corpus callosum | MTX‐TMZ‐R then ASCT | Relapse | 44 | 1,200 | 6 | PR |
| 61 | M | 80 | SCNSL | Uni | Parietal lobe | (a) R‐CVP, (b) R‐CHOP, (c) HD‐MTX | Refractory | 1 | 1,200 | 1 | — |
| 47 | M | 60 | PCNSL | Multi | Cerebellum | HD‐MTX‐TMZ‐R then ASCT | Relapse | 30 | 1,200 | 10 | CR |
| 68 | F | * | PCNSL | Multi | Parieto‐occipital lobe | (a) HD‐MTX, (b) ioMTX, (c) ioMTX | Relapse | 24 | 900 | 1 | — |
| 73 | F | 90 | PCNSL | Multi | Parietal lobe, periventricular, mid brain | MTX‐TMZ‐R, Ara‐C | Relapse | 11 | 1,200 | 3 | PD |
Abbreviations: *, not evaluable; CR, complete response; F, female; HD‐MTX, high‐dose methotrexate; HD‐MTX‐R, high‐dose methotrexate rituximab; ioMTX, intraocular methotrexate; KPS, Karnofsky performance status; M, male; MTXi, methotrexate intrathecal; MTX‐TMZ‐R, methotrexate temozolomide rituximab; OS, overall survival; PCSNL, primary central system nervous lymphoma; PD, progressive disease; PFS, progression‐free survival; PR, partial response; R‐Ara‐C, rituximab cytarabine; R‐CHOP, rituximab cyclophosphamide hydroxydaunomycin oncovin prednisone; R‐CVP, rituximab cyclophosphamide vincristine prednisone; R‐EPOCH, rituximab etoposide prednisone oncovin cyclophosphamide hydroxydaunomycin; SCNL, secondary central system nervous lymphoma; SD, stable disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
